Therapeutic alternatives attempting to counteract the damage caused by AD have yet to achieve permanent successful results, which include acetylcholinesterase inhibitors (AChE) (tacrine, donepezil, rivastigmine, and galantamine) and N-methyl-D-aspartate receptors (NMDARs) (memantine). Here, ACHE is linked to Alzheimer disease.